BioStock: Aqilion’s CEO: “We are driven by dealmaking and scientific data”

With four independent programmes in its pipeline, the Swedish biotech Aqilion is positioned for a series of significant upcoming milestones. CEO Sarah Fredriksson joined BioStock’s studio to share updates on the progress of these programmes, key takeaways from the pre-IND meeting with the FDA, and the lasting impact of Aqilion’s previous major deal with Merck — both within the organisation and in its drive to forge new collaborations.

Watch the interview with CEO Sarah Fredriksson at biostock.se:

https://www.biostock.se/en/2024/10/aqilions-ceo-we-are-driven-by-dealmaking-and-scientific-data/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/